Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study

Bulut E. A. , Alak Z. Y. S. , Dokuzlar O., Kocyigit S. E. , SOYSAL P. , Smith L., ...Daha Fazla

ARCHIVES OF GERONTOLOGY AND GERIATRICS, cilt.88, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM.